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Abstract
α-synuclein (aSyn) is associated with both sporadic and familial forms of Parkinson’s disease (PD), the second most
common neurodegenerative disorder after Alzheimer’s disease. In particular, multiplications and point mutations in
the gene encoding for aSyn cause familial forms of PD. Moreover, the accumulation of aSyn in Lewy Bodies and
Lewy neurites in disorders such as PD, dementia with Lewy bodies, or multiple system atrophy, suggests aSyn
misfolding and aggregation plays an important role in these disorders, collectively known as synucleinopathies. The
exact function of aSyn remains unclear, but it is known to be associated with vesicles and membranes, and to have
an impact on important cellular functions such as intracellular trafficking and protein degradation systems, leading
to cellular pathologies that can be readily studied in cell-based models. Thus, understanding the molecular effects
of aSyn point mutations may provide important insight into the molecular mechanisms underlying disease onset.
We investigated the effect of the recently identified A53E aSyn mutation. Combining in vitro studies with studies in
cell models, we found that this mutation reduces aSyn aggregation and increases proteasome activity, altering
normal proteostasis.
We observed that, in our experimental paradigms, the A53E mutation affects specific steps of the aggregation
process of aSyn and different cellular processes, providing novel ideas about the molecular mechanisms involved in
synucleinopathies.
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Introduction
Parkinson’s disease (PD) is a highly debilitating and pro-
gressive neurodegenerative disorder affecting around
seven million people worldwide. PD is typically known as
a movement disorder, due to the characteristic motor
manifestations associated with the loss of dopaminergic
neurons from the substantia nigra, although it also affects
other areas of the brain. PD and other neurodegenera-
tive disorders, such as demential with Lewy bodies, and
multiple system atrophy, are also characterized by the
accumulation of aggregated alpha-synuclein (aSyn) in
proteinaceous inclusions known as Lewy bodies (LBs)
or Lewy neurites [54]. Together, these diseases are
known as synucleinopathies [17, 55]. However, it is still
unclear whether LBs are themselves toxic or protective
[7, 43], with smaller oligomeric species of aSyn being
the culprits as recent studies suggest [31, 45, 58, 63].
aSyn is a disordered and abundant neuronal protein
whose normal function is still elusive. Familial forms of
PD associated with duplication and triplication of the
SNCA gene [53], along with studies of aSyn overexpres-
sion, in cellular and animal models, suggest the protein
may acquire a toxic function. The cellular pathologies
associated with increased levels and accumulation of
aSyn include disruption of vesicular transport [6, 42],
mitochondrial dysfunction, impairment of autophagy
and proteasome, and oxidative stress [2, 21], suggesting
aSyn plays a multitude of roles in the cell, perhaps due
* Correspondence: touteir@gwdg.de
†Equal contributors
1Department of Neurodegeneration and Restorative Research, University
Medical Center Göttingen, Waldweg 33, 37073 Göttingen, Germany
3Chronic Disease Research Center (CEDOC), NOVA Medical School, Campo
dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lázaro et al. Acta Neuropathologica Communications  (2016) 4:128 
DOI 10.1186/s40478-016-0402-8
to its intrinsically disordered nature. Under physiological
conditions, aSyn is considered to be a pre-synaptic protein
[37] that associates with vesicles and membranes [11].
According to the “Braak hypothesis”, PD pathology
is thought to start from the periphery (gut or nose),
and progress until it reaches the brain [4, 5, 49],
spreading in a prion-like manner [20, 29, 36]. However,
this hypothesis is still controversial, and the molecular
mechanisms underlying this phenomenon are not fully
understood [25].
The vast majority of PD cases are sporadic but single
point mutations in the gene encoding for aSyn (SNCA)
cause familial forms of the disease [10]. The most recently
identified aSyn mutation causes the substitution of alanine
at position 53 by a glutamate residue (A53E), identified in
a 36 year-old Finnish patient with atypical PD. The patient
displayed a dense accumulation of SNCA inclusions in the
striatum and a severe cortical pathology, affecting both
the superficial and deep laminae [3]. In vitro, the A53E
mutation was shown to reduce aSyn aggregation and fi-
bril formation without changing the secondary structure
content of the protein, when compared to WT aSyn [15].
These data suggest that the negatively charged glutamate
residue may affect the folding and, consequently, the ag-
gregation process of the protein.
In our study, we conducted a detailed study of the ef-
fects of the A53E mutation on aSyn using a combination
of in vitro and cellular models of aSyn oligomerization
and aggregation [40, 45]. Our results showed that the
A53E mutation modulates aSyn aggregation in vitro and
in vivo and impacts on distinct cellular pathways.
Altogether, the study of specific aSyn mutants provides
novel insight into the spectrum of functions and cellular
pathologies associated, opening novel avenues for the
design of therapeutic strategies for PD and other
synucleinopathies.
Materials and methods
Protein expression and purification
pET21a vectors (Novagen) encoding for WT aSyn and
the A53E mutant were transformed into E. coli BL21
(DE3) cells. For protein expression, 10 ml overnight
culture of transformed cells was used to inoculate 1 L
of LB medium with 100 μg/mL ampicillin, which was
further incubated at 37 °C and 250 rpm. At an OD600
0.6, protein expression was induced with 1 mM of
isopropyl-1-thio-β-D-galactopyranoside (IPTG) for 4 h
at 37 °C. Afterwards, the cultures were centrifuged and
the cell pellet frozen at −80 °C.
For cell lysis, pellets were resuspended in 15 mL of
lysis buffer (50 mM Tris · HCl, 150 mM NaCl, 1 μg/mL
Pepstatin A, 20 μg/ml Aprotinin, 1 mM Benzamidine,
1 mM PMSF and 1 mM EDTA) and sonicated on ice.
The lysate was boiled for 10 min at 95 °C and soluble
and insoluble fractions were separated by centrifugation
at 48,384 × g, for 15 min. 136 μL/mL of 10% strepto-
mycin sulfate and 228 μL/mL of glacial acetic acid was
added to the supernatant. The resulting solution was
centrifuged for 5 min at 48,384 × g, and the supernatant
was collected and precipitated with saturated ammo-
nium sulphate at 4 °C in a ratio 1:1 (v/v) with the super-
natant. The pellets were washed with a 1:1 (v/v) solution
of ammonium sulphate and water. The pellets were re-
suspended in 900 μL of ammonium acetate 100 mM and
the same volume of 100% ethanol was added to precipi-
tated aSyn.
Purification protocol was as adapted from [59]. Briefly,
ethanol precipitated aSyn was resuspended in starting
buffer (25 mM Tris · HCl at pH 8.0) and filtered through
a Millex-HP filter syringe-driven filter unit (0.45 μm,
Millipore). Anion exchange high-performance liquid-
chromatography was carried out on an AKTA-FPLC (GE
Healthcare). The sample was loaded, bounded to Hi-
Trap column (GE Healthcare) and eluted with a NaCl
linear gradient of elution buffer (25 mM Tris · HCl at
pH 8.0, 1 M NaCl). The fractions containing aSyn were
collected and buffer was exchanged for 20 mM ammo-
nium acetate. The identity, and purity of the recombin-
ant proteins was assessed by Mass Spectrometry and
SDS-PAGE being higher than 99%.
Aggregation assays
The protein stocks were prepared by resuspending ly-
ophilized protein in native buffer (10 mM sodium phos-
phate at pH 7.0) to a concentration of approximately
100 μM. Then, the protein stocks were filtered through
0.22 μm filter unit. The integrity of the protein and the
absence of soluble oligomers at the beginning of the re-
action was confirmed by gel filtration chromatography
in a Superdex 75 10/300 column (GE Healthcare Life
Sciences). Three aliquots of 300 μL of aSyn WT and
A53E mutant were prepared from the protein stocks, in
native buffer to a final concentration of 60 μM. Samples
were incubated in an Eppendorf Thermomixer Comfort
(Eppendorf, USA) with 0.02% sodium azide at 600 rpm
and 37 °C.
Light scattering spectroscopy
The transition of aSyn from initial soluble monomeric
form to aggregated state was determined by measuring
light scattering in a Jasco FP-8200 spectrofluorometer
(Jasco Inc, MD, USA) with an excitation wavelength of
330 nm and emission range from 320 to 340 nm at 25 °C.
Final protein concentration was 10 μM in native buffer.
Solutions without protein were used as negative controls.
All experiments were carried out in triplicates.
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Thioflavin T binding assay
Th-T binding to amyloid fibrils was recorded using a
JASCO FP-8200 spectrofluorometer (Jasco Inc, MD,
USA) with an excitation wavelength of 445 nm and
emission range from 460 to 600 nm at 25 °C, using a slit
width of 5 nm for excitation and emission. The final
concentration of Th-T was 25 μM and final protein con-
centration was 10 μM in native buffer. Solutions without
protein were used as negative controls. All experiments
were carried out in triplicates.
Congo red binding assay
CR binding to amyloid fibrils was tested using a Cary-
400 Varian spectrophotometer (Varian Inc., Palo Alto,
CA, USA) by recording the absorbance spectra from 375
to 675 nm, at 25 °C. A final concentration of 10 μM CR
was added to 10 μM protein samples in native buffer.
Protein solutions in the presence and absence of CR
were used to calculate the differential CR spectra. All ex-
periments were carried out in triplicates.
Transmission electron microscopy (TEM) assays
For negative staining, incubated samples were diluted in
Mili-Q water to 10 μM and 10 μL were then placed on
carbon-coated copper grids, and left to stand for 5 min.
The grids were washed with distilled water and stained
with 2% (w/v) uranyl acetate for 1 min. The morphology
of aggregates of WT and A53E aSyn was observed using
a JEOL JEM 1400 transmission electron microscope
(JEOL, USA) at an accelerating voltage of 120 kV. The
width of fibrils for WT and necklace-like structures for
A53E was measured using ImageJ (250 measurements).
Results are provided as Mean ± SE.
ATR-FTIR spectroscopy
Attenuated total reflectance Fourier transform infrared
spectroscopy (ATR FT-IR) analysis of amyloid fibrils was
performed using a Bruker Tensor 27 FTIR Spectrometer
(Bruker Optics Inc.) with a Golden Gate MKII ATR
accessory. Incubated samples were centrifuged and the
insoluble fraction was resuspended in water. Each spectrum
consists of 16 independent scans, measured at a spectral
resolution of 4 cm−1 within the 1800–1500 cm−1 range.
Second derivatives of the spectra were used to determine
the frequencies at which the different spectral components
were located. FTIR spectra were fitted to overlapping
Gaussian curves using PeakFit package software (Systat
Software).
Aggregation kinetics
Aggregation of aSyn, departing from soluble monomeric
form, was monitored by measuring the transition from
non-aggregated to aggregated state according to the Th-T
fluorescence at 486 nm on a 96-wells microplate reader
for 72 h at 37 °C (Victor Microplate reader, Perkin Elmer,
USA). The reactions were carried out with 70 μM soluble
purified WT and A53E aSyn in native buffer. Experiments
were carried out in triplicates.
Sedimentation assay
aSyn aggregation was measured by sedimentation using
centrifugation. The incubated samples of WT and A53E
mutant were centrifuged at 48,384 × g for 30 min, and
the supernatants were carefully removed. The amount of
soluble aSyn was measured by absorbance at 280 nm
using aSyn extinction coefficient Ɛ280 = 5960 M
−1/cm−1,
before and after centrifugation. All measurements were
carried out in triplicates.
Primer design
The primers were designed according with the manufac-
turer’s instructions (Table 1).
Generation of A53E aSyn constructs for expression in
mammalian cells
A53E was inserted in the Venus-BiFC system [45] or
SynT [40] by site-directed mutagenesis (QuickChange II
Site-Directed Mutagenesis Kit, Agilent Technologies, SC,
USA) following the manufacturer’s instructions. All con-
structions were confirmed by sequencing.
Cell culture
Human Embryonic Kidney 293 (HEK) cells were grown
in Dulbecco’s Modified Eagle Medium (DMEM, Life
Technologies- Invitrogen, Carlsbad, CA, USA), and hu-
man neuroglioma cells (H4) in Opti-MEM I with Gluta-
max (Life Technologies- Gibco, Carlsbad, CA, USA),
both supplemented with 10% Fetal Bovine Serum Gold
(PAA, Cölbe, Germany) and 1% Penicillin-Streptomycin
(PAN, Aidenbach, Germany). Cells were grown at 37 °C,
with 5% of CO2.
Cell transfection
HEK cells
The day before transfection, 100 000 cells were plated in
12-well plates (Costar, Corning, New York, USA). The
cells were transfected with equimolar amounts of the plas-
mids using Metafectene (Biotex, Munich, Germany) as
specified by the manufacturer. After twenty-four hours,
the cells were collected or stained for further analysis.
Table 1 Primers used to perform site-directed mutagenesis and
generate the A53E mutant
A53E forward 5′ GAGTGGTGCATGGTGTGGAAACAGTGGCTGAGAAGAC 3′
A53E reverse 5′ GTCTTCTCAGCCACTGTTTCCACACCATGCACCACTC 3′
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H4 cells
Eighty thousand cells were plated in 12-well plates (Costar,
Corning, New York, USA). After 24 h, equal amount of
SynT and Synphilin-1 were transfected using FuGENE6
Transfection Reagent (Promega, Madison, USA) in a ratio
of 1:3 according to the manufacturer’s recommendation.
Forty-eight hours after transfection, the cells were proc-
essed for different assays.
Immunocytochemistry
After transfection, cells were fixed with 4% paraformal-
dehyde at room temperature (RT), followed by a
permeabilization with 0.5% Triton X-100 (SigmaAldrich,
St. Louis, MO, USA). The cells were blocked in 1.5%
normal goat serum (PAA, Cölbe, Germany)/1xPBS
(1.37 M NaCl, 27 mM KCl, 101.4 mM Na2HPO47
.H2O,
16.7 mM KH2PO4), and then incubated with primary
antibody. Primary antibodies used in this study were:
mouse Syn1 (1:1000, BD Transduction Laboratory, New
Jersey, USA) or rabbit anti-aSyn (1:1000, Abcam, Boston,
USA), anti-Giantin (1:1000, Abcam, Boston, USA), aSyn-
S129 1:1000 (Wako Chemicals USA, Inc., Richmond,
USA) overnight, and secondary antibody (Alexa Fluor
488 donkey anti-mouse IgG and/or Alexa Fluor 555 goat
anti rabbit IgG, (Life Technologies- Invitrogen, Carlsbad,
CA, USA)) for 2 h at RT. Cells were finally stained with
Hoechst 33258 (Life Technologies- Invitrogen, Carlsbad,
CA, USA) (1:5000 in DPBS) for 5 min, and maintained
in 1xPBS for imaging.
Yeast transformation and plasmids
The p426GAL-aSyn-GFP plasmid carries the human
gene of aSyn with a C-terminal fusion to GFP, under the
regulation of GAL1 inducible promoter [44]. This plas-
mid was used to generate aSyn A53E by site directed
mutagenesis. The yeast cells W303-1A (MATa; can1-
100; his3-11,15; leu2-3,112; trp1-1; ura3-1; ade2-1) were
transformed with the indicated plasmids using lithium
acetate standard method [16].
Yeast growth
For all experiments, an inoculum was prepared to obtain
cells in log growth phase, using synthetic complete (SC)
medium [0.67% (w/v) yeast nitrogen base without amino
acids (Difco), 1% (w/v) raffinose and 0.79 g.L−1 complete
supplement mixture (CSM) (QBiogene)], 200 rpm, 30 °C,
as we described [57]. To induce aSyn expression, in liquid
medium, cells were grown (OD600 nm 0.2) in SC selective
medium 1% (w/v) galactose (aSyn ON) for 7 h at 30 °C,
200 rpm. aSyn cytotoxicity was evaluated by spotting as-
says. OD600 nm was set to 0.1 ± 0.005 and 1:10 serially dilu-
tions of each sample were prepared [57]. Then, 4 μL of
each dilution was spotted in solid SC selective medium
containing 2% glucose (aSyn OFF) or 1% (w/v) galactose
(aSyn ON) and incubated at 30 °C for 36–42 h. Images
were acquired using ChemiDoc Touch (Bio-Rad).
Fluorescence microscopy
HEK cells expressing the aSyn Venus-BiFC assay were
visualized using the Olympus IX81-ZDC microscope
system, with a 20× objective. One hundred images were
randomly taken out of four independent experiments.
Total intensity was measured using the Olympus Scan^R
Image Analysis Software.
In order to determine the percentage of yeast cells
with aSyn inclusions, cells were grown as described
above and GFP fluorescence was visualized with a Zeiss
Z2 Widefield Fluorescence microscope. The percentage
of cells presenting aSyn inclusions was then determined
by counting at least 300 cells for each treatment using
ImageJ software.
Quantification of aSyn inclusions
Cells expressing aSyn were scored according with the
presence or absence of inclusion on transfected cells.
Three independent experiments were performed, and
the results were expressed as the percentage of the total
number of transfected cells.
Thioflavin S staining
Freshly prepared, 0.5% of Thio-S (Sigma-Aldrich, St. Louis,
MO, USA) was incubated within the cells for 5 min. The
cells were washed three times with 80% ethanol, and main-
tained in 1xPBS for fluorescence microscopy.
Quantification of Golgi fragmentation
Golgi morphology was assessed in transfected HEK and
H4, and scored into three groups, was we previously
published [32] (normal, diffused and fragmented). Three
independent experiments were performed.
Western blot analysis
HEK and H4 cells were lysed with Radio-Immunopre-
cipitation Assay (RIPA) lysis buffer (50 mM Tris pH 8.0,
0.15 M NaCl, 0.1% SDS, 1% NP40, 0.5% Na-
Deoxycholate), 2 mM EDTA and a Protease Inhibitor
Cocktail (1 tablet/10 mL) (Roche Diagnostics, Mannheim,
Germany). Protein concentration was determined by
Bradford assay (BioRad Laboratories, Hercules, CA, USA),
and the sample were denaturation for 5 min at 100 °C in
protein sample buffer (125 mM of 1 M Tris HCl pH 6.8,
4% SDS 0,5% Bromophenol blue, 4 mM EDTA, 20%
Glycerol, 10% b-Mercapto ethanol). The gels were loaded
with 80 μg protein, and the samples separated on 12%
SDS-polyacrylamide gels. The gel was transferred to a
PVDF membrane using a Trans-Blot Turbo transfer system
(BioRad), according to the manufacturer’s instructions.
Membranes were blocked with 5% (w/v) skim milk (Fluka,
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Sigma-Aldrich, St. Louis, MO, USA), and incubated with
Syn1 (1:1000, BD Biosciences, San Jose, CA, USA), and
1:2000 anti-b-actin (Sigma-Aldrich, St. Louis, MO, USA)
overnight at 4 °C. After washing, the membranes were
incubated for 1 h with secondary antibody, anti-mouse
IgG, or anti-rabbit IgG, horseradish peroxidase labeled
secondary antibody (GE Healthcare, Bucks, UK) at
1:10,000. Proteins were detected by ECL chemiluminescent
detection system (Millipore, Billerica, MA, USA) in Fusion
FX (Vilber Lourmat). The band intensity was estimated
using the ImageJ software (NIH, Bethesda, MD, USA) and
normalized against b-actin.
For aSyn quantification total yeast protein extraction
and western blot was performed following standard pro-
cedures as described before [57]. Antibodies used: aSyn
(BD Transduction Laboratories, San Jose, CA, USA),
pS129-aSyn (Wako Chemicals USA, Inc., Richmond VA,
USA) PGK (Life Technologies, PaisleyUK). Triton soluble
and insoluble fractions were processed and analyzed as de-
scribed before [56].
Native PAGE
For native PAGE, HEK cells were lysed in 1xPBS pH 7.4
with Protease Inhibitor Cocktail tablet and separated in
4–16% gradient Native pre-cast gel (SERVA Electrophor-
esis GmbH, Heidelberg, Germany). Gels were run accord-
ing to the manufacturer’s instructions, and transferred as
previously described.
Proteinase K digestion
H4 cells samples were digested with Proteinase K
(2.5 μg/mL) (Roth, Carlsbad, Germany) for 1, 3, and
5 min at 37 °C. The enzyme reaction was stopped with
protein sample buffer, and the samples were separated
in a SDS-page gel, as described above.
Flow cytometry (FCM)
FCM was performed in a BD FACSCanto II. To analyze
cell viability yeast cells transformed with the indicated
plasmids were incubated with 5 μg.mL−1 PI, for 15 min
at 30 °C, 200 rpm and protected from light. Cells were
then washed with PBS and used to FCM. A minimum of
10,000 events were collected for each experiment. Re-
sults were expressed as median fluorescence intensity
(MFI) of a molecule.
Measurement of 26S Proteasome Catalytic Activity
The chymotrypsin-like activity of the 26S proteasome
was determined has previously described [27]. Briefly,
after 48 h transfected cells were collected in lysis buffer
(50 mM Tris, pH 7.5, 250 mM Sucrose, 5 mM MgCl2,
1 mM DTT, 0.5 mM EDTA, 0.025% Digitonin, 2 mM
ATP). The reaction was initiated with 15 μg from the total
protein lysates, together with the addition of reaction buffer
(50 mM Tris (pH 7.5), 40 mM KCl2, 5 mM MgCl2, 1 mM
DTT, 0.5 mM ATP, 100 μM Suc-LLVYAMC) were mix in
100 μl final volume. The fluorescence of AMC (380 nm ex-
Citation and 460 nm emission) was monitored in a micro-
plate fluorometer (Infinite M1000, Tecan) at 37 °C. As
control, proteasome was inhibited with 20 μM MG132
(Sigma, Hamburg, Germany) prior to the measurements.
Statistical analyses
Data were analyzed using GraphPad Prism 6 (San Diego
California, USA) software and were expressed as the
mean + − SD. Statistical differences from WT aSyn were
calculated using unpaired Student t-test and one-way
ANOVA with post-hoc Tukey’s test. Significance was
assessed for, where * corresponds to p < 0.05, ** corre-
sponds to p < 0.01 and *** corresponds to p < 0.001.
Results
A53E mutant forms protofibrils by reducing aSyn
fibrilization
To understand the effect of the A53E substitution in the
aggregation process of aSyn (Fig. 1a), we assembled a
pipeline of both in in vitro and cellular studies, in hu-
man and yeast cells (Fig. 1b), and conducted a battery of
experiments to characterize the behavior of this recently
identified aSyn mutant form.
We started to compare the in vitro aggregation prop-
erties of WT and A53E aSyn using synchronous light
scattering, sedimentation and binding to amyloid-binding
dyes. For these assays, the soluble forms of both proteins
were incubated at 60 μM under agitation at 37 °C for two
weeks. The light scattering signal was 6-fold higher for
WT aSyn than for the A53E mutant, suggesting differ-
ences in aggregation process (Fig. 2a). Using spectropho-
tometry, we quantified the levels of aggregated protein in
both solutions after separating aSyn in two fractions (sol-
uble and insoluble), by centrifugation. The amount of pro-
tein in the insoluble fraction in the WT aSyn preparation
was two times higher than with A53E (*p < 0.05, Fig. 2b).
The presence of amyloid fibrils can be detected in vitro
using Thioflavin T (Th-T), a dye that specifically binds to
amyloid fibrils [35, 51]. In agreement with light scattering
and sedimentation data, we found that the Th-T fluores-
cence signal was 10 times lower for A53E than for WT
aSyn (Fig. 2c). The presence of amyloid fibrils can be fur-
ther detected by monitoring the increase of the absorb-
ance of Congo Red (CR) and the red shift of the dye
absorbance maximum [28]. The binding of A53E to CR
was negligible, since the peak of absorbance in the pres-
ence of A53E aSyn was similar to that of free CR (Fig. 2d).
In contrast, we observed a dramatic spectral change in CR
for WT aSyn (Fig. 2d). To confirm the different amyloido-
genic propensities of WT and A53E aSyn, we analyzed the
morphological features of the aggregates formed using
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transmission electron microscopy (TEM). Although we
detected the presence of higher order complexes in both
preparations, their size and morphology was different. For
WT aSyn, we observed the typical long and unbranched
amyloid fibrils (Fig. 2e), 11.6 ± 0.4 nm with a width of
11.6 ± 0.4 nm (Fig. 2e). In contrast, the structures
formed by A53E aSyn exhibited a protofibrillar appearance,
with small round oligomeric structures that seemed to be
linked in a necklace fashion, with a width of 28.5 ± 0.7 nm
(Fig. 2f-g).
To assess the secondary structure content of the as-
semblies formed by WT and A53E aSyn, we analyzed the
amide I region of the FTIR spectrum (1700–1600 cm−1).
This region of the spectrum corresponds to the absorp-
tion of the carbonyl peptide bond of the main amino
acid chain of the protein, and is a sensitive marker of
the protein secondary structure. After deconvolution of
the FTIR spectra of the aSyn solutions, we were able to
assign the individual secondary structure elements and
their relative contribution to the main absorbance signal
at the end of the aggregation reaction (Fig. 2g and h and
Table 2). The absorbance spectra were radically different
for WT and A53E aSyn. While the spectrum of WT aSyn
was dominated by a peak at 1625 cm−1, attributable to
the presence of amyloid-like inter-molecular β–sheet
structure (Fig. 2g), the spectrum of the A53E mutant
was dominated by a peak at 1649 cm−1 corresponding to
disordered/random coil conformation (Fig. 2h).
Next, we monitored how the mutation impacted on
the aggregation kinetics of aSyn by continuously moni-
toring the changes in Th-T binding over time for WT
and A53E variants. The kinetics of amyloid fibril forma-
tion usually follows a sigmoidal curve that reflects a
nucleation-dependent growth mechanism. The aggrega-
tion of both proteins followed this pattern, with an ap-
parent lag phase of 8 h (Fig. 2i). After this lag phase, the
two aggregation reactions diverged significantly, with an
exponential increase for WT aSyn that plateaued at
around 55 h, and a steady and much slower increase for
A53E aSyn, reaching a 3.5-times lower fluorescence in-
tensity. Altogether, our data demonstrates that the A53E
mutation reduces aSyn amyloid formation in vitro.
The A53E mutation decreases aSyn oligomerization in
cellular models
We next investigated the effects of the A53E mutation
on the behavior of aSyn in the context of living human
cell models. First, we used the Bimolecular Fluorescence
Fig. 1 Aggregation process and study design. a aSyn aggregation process in cell models. b Experimental design used in the study. In vitro
studies and studies in cell models were used to assess the effect of the A53E mutation on aSyn
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Fig. 2 (See legend on next page.)
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Complementation (BiFC) assay to monitor aSyn
oligomerization, as we previously described [45]. Briefly,
non-fluorescence Venus fragments are fused to either the
N- or C-terminus of aSyn and, upon dimerization/
oligomerization of the protein, the fluorophore is reconsti-
tuted resulting in fluorescence signal. While this assay in-
volves the tagging of aSyn with fragments of fluorescent
proteins, it constitutes a powerful paradigm to assess aSyn
oligomerization. We observed that A53E aSyn, similarly
to WT, formed dimers/oligomers (Fig. 3a). However,
the fluorescence signal was lower than that observed
with WT aSyn, suggesting differences in the dimerization/
oligomerization process (**p < 0.01) (Fig. 3b), since the
levels of expression of WT and A53E aSyn were identical
(Fig. 3c and d, Additional file 1: Figure S2.1 and Additional
file 1: Figure S2.2). We also found that the A53E mutant
produced high molecular weight species, similar to WT
aSyn (Fig. 3e). Thus, we refer to the species formed as
oligomers, for simplicity.
The A53E mutation alters the biochemical properties of
aSyn inclusions
Next, we investigated if the later stages of the aSyn ag-
gregation process were altered by the A53E mutation.
For that, we used a well-established cell-based aggrega-
tion model that consists in the co-expression of SynT
(C-terminally modified aSyn) and Synphilin-1 [40], since
expression of aSyn alone does not result in inclusion for-
mation. In this aSyn aggregation model, aSyn inclusions
are readily detected by immunocytochemistry using anti-
bodies against aSyn, allowing the characterization of differ-
ent types of inclusions [32], and screening modulators of
aSyn aggregation [41]. 48 h after transfection, we analyzed
inclusion formation in the cells (Fig. 4a), and observed that
the A53E mutation did not alter inclusion formation when
compared to WT aSyn (Fig. 4b). Again, no differences in
the levels of aSyn or Synphilin-1 were detected between
WTand A53E mutant aSyn (Fig. 4c-e).
aSyn is phosphorylated on Serine 129 (pS129) in LBs
found in the brains of PD patients, linking this post-
translational modification with disease [14, 52]. We pre-
viously showed that specific aSyn mutations, such as the
E46K, can alter pS129 on aSyn [39]. Thus we investigated
the effect of the A53E mutation on S129 phosphorylation.
We found that both WT and A53E aSyn inclusions were
positive for pS129 (Fig. 4f).
To further investigate the biochemical nature of the
inclusions formed by the A53E aSyn mutant, we stained
the cells with Thioflavin S (Th-S), a dye that binds to β-
sheet rich amyloid structures [33]. We observed that the
larger inclusions formed by WT and A53E aSyn stained
positive for Th-S (Fig. 4g). In addition, we also used pro-
teinase K (PK) resistance as a marker of aggregate for-
mation, as protein inclusions tend to be more resistance
to PK digestion. Interestingly, we found that the A53E
mutant was less resistant when compared to WT aSyn
(Fig. 4h and i), suggesting the inclusions formed by the
A53E mutant have a less-compact nature than those
formed by the WT protein.
The ubiquitin-proteasome system (UPS) is the major
non-lysosomal pathway for selective protein degradation.
In cell models, it has been shown that aSyn accumula-
tion can affect the activity of the UPS system [61]. In
our experimental conditions, we observed that cells ex-
pressing A53E aSyn mutant display increased proteolytic
activity of the proteasome (Fig. 4j and k).
(See figure on previous page.)
Fig. 2 Aggregation properties of WT and A53E aSyn variants. aSyn WT and A53E mutant, prepared at 60 μM in 10 mM sodium phosphate,
pH 7.0, were incubated for 2 weeks under agitation at 37 °C. a Static light scattering of 10 μM aSyn in 10 mM sodium phosphate, WT (solid line)
and A53E mutant (dashed line). b Distribution of aSyn between the soluble and insoluble fractions. c Fluorescence emission spectra of Th-T upon
incubation with 10 μM aSyn WT (solid line) and A53E mutant (dashed line). Free Th-T emission spectrum is represented in grey. d CR absorbance
spectra in the presence of 10 μM aSyn WT (solid line) and A53E mutant (dashed line). Free CR absorbance spectrum is represented in grey.
f-g Morphology of WT and A53E aSyn aggregates TEM micrographs. Negatively stained aggregates formed by aSyn WT (left panel) and A53E
mutant (right panel) incubated for two weeks. h-i Secondary structure of WT and A53E aSyn aggregates. Secondary structure content of the aSyn
WT and A53E mutant after two weeks incubation. ATR-FTIR absorbance spectra in the amide I region was acquired (thick line) and the fitted
individual bands after Gaussian deconvolution are shown (thin lines). i Aggregation kinetics of WT and A53E aSyn. Aggregation kinetics of aSyn
were monitored by following the changes in relative ThioT fluorescence emission. Concentration of protein was 70 μM WT aSyn (crosses) and
A53E mutant (dots) in a final volume of 150 μL. The evolution of Th-T fluorescence in the absence of protein is represented in grey, n = 3
Table 2 Assignment of secondary structure components of aSyn variants in the amide I region of the FTIR spectra
WT A53E
Band (cm−1) Area (%) Structure Band (cm−1) Area (%) Structure
1 1625 40 β -sheet (inter) 1628 24 β -sheet (inter)
2 1645 22 1649 38
3 1663 25 Loop/β-turn/bend/α-helix 1666 25 Loop/β-turn/bend/α-helix
4 1680 13 β-turn 1681 14 β-turn
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aSyn aggregation leads to Golgi fragmentation
aSyn induces several cellular pathologies that have been
documented over the years and are routinely used to as-
sess the effect of specific mutations or genetic interactors
[60]. One particular type of cellular pathology associated
with aSyn toxicity is the fragmentation of the Golgi appar-
atus [13]. This is also evident in other neurodegenerative
diseases [18], suggesting it might be a more general re-
sponse to the proteotoxicity associated with protein mis-
folding and aggregation. To assess whether expression of
A53E mutant aSyn affected the integrity of the Golgi, we
analyzed the morphology of this organelle in both the
aSyn oligomerization and aggregation models (Fig. 5a and
c). We classified the morphology of the Golgi as normal,
diffuse and fragmented, as we previously described [32].
In the oligomerization model, we observed that WT
aSyn reduced the percentage of cells exhibiting normal
Golgi morphology (~40%, ***p < 0.001 Fig. 5a and b and
Additional file 1: Figure S3.1–3.3), as we previously
reported [32]. However, in cells expressing the A53E
mutant the effects were not as pronounced as with
WT, and the phenotype was more similar to that of
cells carrying an empty vector (~70% and 80% of the
transfected cells displayed normal Golgi morphology for
A53E, and empty vector, respectively) (*p < 0.05) (Fig. 5b
and Additional file 1: Figure S3.1).
In the aSyn aggregation model, we observed the op-
posite effect. Around 50% of the cells expressing the
A53E SynT displayed normal Golgi morphology whereas
around 70% of the cells expressing WT SynT displayed
normal Golgi (Fig. 5c and d and Additional file 1: Figure
S2.4–2.6; ***p < 0.001 and *p < 0.01 for empty vector, and
WT, respectively). This suggests that the aggregation of
A53E aSyn induces Golgi alterations.
A53E aSyn behaves identically to WT aSyn in yeast cells
Yeast cells have been extremely useful to assess cellular
pathologies associated with the expression of aSyn. Thus,
Fig. 3 A53E reduces aSyn oligomerization. a Fluorescent cells, expressing VN-aSyn and aSyn-VC constructs, as a result of the aSyn interaction.
Scale bar: 30 μm. b Mean fluorescence intensity of cells were assessed 24 h post-transfection using an Olympus IX81-ZDC microscope. For each
condition, 100 pictures were acquire in 4 independent experiments were conducted. Student’s t test (**p < 0.01). c-d aSyn protein levels were
assessed by immunoblot analysis and were found to similar between WT aSyn and the A53E mutant. n = 3. e Native-PAGE gel showed that the
A53E mutant forms high molecular weight species similar to WT aSyn
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Fig. 4 (See legend on next page.)
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in order to assess if the A53E mutation alters the cytotox-
icity and aggregation of aSyn, we expressed this mutant in
S. cerevisiae and monitored phenotypes previously estab-
lished [44]. We expressed WT or mutant A53E aSyn fused
to eGFP using multi-copy (2 μ) plasmids and under the
regulation of a galactose-inducible promoter (GAL1). aSyn
cytotoxicity was first evaluated by a spotting assay. The
growth of the cells expressing A53E aSyn was compared
to that of cells expressing WT aSyn (Fig. 6a). As described
before, expression of WT aSyn is toxic and results in re-
duced cell growth (Fig. 6a). We found that cells expressing
A53E aSyn display a similar phenotype, suggesting that
this familial mutation does not significantly affect aSyn
toxicity in yeast (Fig. 6a). To further dissect the cytotox-
icity of the A53E mutant, we performed propidium iodide
(PI) staining and flow cytometry analysis, a readout of
plasma membrane integrity (Fig. 6b). We observed that,
7 h after induction of aSyn expression, no significant dif-
ferences were observed between cells expressing either
WT or the A53E aSyn (Fig. 6b).
Next, we evaluated the subcellular distribution of the
A53E mutant aSyn, using fluorescence microscopy. 7 h
after induction of aSyn expression we assessed inclusion
formation in the cells (Fig. 6c). The expression of A53E
aSyn resulted in the formation of cytoplasmic inclusions
that looked similar to those formed in cells expressing
aSyn WT (Fig. 6c). In addition, no significant differences
were observed in the percentage of cells with inclusions
between WT and the A53E (Fig. 6c). We also evaluated
the levels of aSyn expression by immunoblot analyses
and found that both proteins were expressed at similar
levels (Fig. 6d). The levels of phosphorylation on serine
129 were also indistinguishable between WT and A53E
mutant aSyn (Fig. 6d).
Discussion
aSyn plays a major role in the pathological processes in-
volved in neurodegenerative diseases, like PD or Dementia
with Lewy Bodies [26]. When overexpressed in cells, to
mimic familial forms of PD associated with multiplications
of the aSyn gene, aSyn can promote cytotoxicity and
impair vital processes, thereby contributing to cell death
[9, 38, 44]. However, the precise molecular mechanisms
underlying aSyn toxicity are still unclear, compromising
our ability to intervene therapeutically. Both mutations
and multiplications of the SNCA gene cause familial forms
of PD [8, 22, 64]. Currently, six missense mutations in
aSyn have been associated with autosomal dominant
forms of parkinsonism (A30P, E46K, H50Q, G51D, A53E,
A53T) [1, 30, 34, 46–48, 65]. Of these, the A53E was
the last one to be identified and, therefore, has been
less investigated.
In this study, we aimed to investigate the effect of the
substitution of the alanine at position 53 by a glutamic
acid residue that introduces an additional negative charge
in the protein. For this purpose, we used in vitro tech-
niques to characterize the biophysical effects of the muta-
tion, and exploited cell-based models to assess the effects
of the expression of the A53E mutant on the distribution,
aggregation, and toxicity of the protein.
In vitro, we observed that A53E attenuates aSyn aggre-
gation and reduces amyloid fibril formation when com-
pared to WT aSyn. In fact, the formation of amyloid
structures by the A53E mutant is marginal, since A53E
is unable to bind CR. Overall, these observations are in
line with a previous report showing that the presence of
a negatively-charged residue can reduce the intrinsic ag-
gregation propensity of aSyn [15]. Nevertheless, because
the change in net charge in aSyn is small, −9 and −10
for the WT and A53E proteins, respectively, the effect
this mutation has on aggregation has more likely a local
origin. We used the Amylpred2 consensus aggregation
predictor to analyze if the A53E mutation might have an
impact in the intrinsic aggregation propensity of the
aSyn sequence. Amylpred2 identifies a hot spot of aggre-
gation corresponding to the 49–55 sequence stretch
(VHGVATV), including Ala53. The A53E mutation
shortens the aggregation region now including only resi-
dues 49–53 (VHGVE). The AGGRESCAN algorithm en-
ables the comparison of the aggregation propensity of
the two regions, showing that it is 2.1 lower for A53E
than for WT aSyn.
In the context of a cell, the behavior of a protein is
subjected not only to the crowded environment but also
to the action of various protein quality control mecha-
nisms. In human cells, we observed that the A53E muta-
tion reduces aSyn oligomerization without changing the
aggregation pattern. Interestingly, the inclusions formed
(See figure on previous page.)
Fig. 4 A53E does not change the inclusion pattern. a-b At least 50 cells per condition were classified according to the pattern formed. We
observed that A53E did not change the number of inclusions per cells. n = 3. Scale bar: 30 μm. c-e Immunoblot analysis of the aSyn and
Synphilin-1 levels showed no significant differences in expression of WT or A53E aSyn. n = 3 (f) Inclusions formed by WT and A53E are positive for
pS129. Positive inclusions are indicated with white arrows. Scale bar: 30 μm. g Inclusions were stained with Th-S and analyzed via fluorescence
microscopy. As indicated with arrow heads, we observed that some inclusions displayed amyloid-like properties, by staining positive with Th-S.
Scale bar: 30 μm. h-i WT and A53E aSyn protein lysates were digested with PD for different times (1, 3 and 5 min). After normalization of the
values to the undigested condition, we observed that A53E inclusions are less resistant to PK-digestion. n = 2. j-k 48 h post-transfection the cells
were collected and we assessed the activity of the proteasome. We observed that cells expressing A53E mutant increased proteolytic activity of
the proteasome in comparison with WT. n = 3. Student’s t test (*p < 0.05, **p < 0.01)
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by A53E aSyn are more sensitive to PK digestion than
those formed by WT aSyn, suggesting that the inclusions
formed are less compact or, possibly, more immature. The
negative charge introduced by the glutamate residue can
perhaps alter the intermolecular interactions between aSyn
molecules, and prevent the formation of tighter inclusions.
This may also correlate with the increase in proteasome ac-
tivity that we observed, since this is an important degrad-
ation system to eliminate soluble proteins and smaller
assemblies that are not degraded by autophagy.
In our previous studies, we did not observe major differ-
ences when comparing another PD-associated aSyn mutant
Fig. 5 Golgi morphology in the oligomerization and aggregation models. a-b Representative pictures of transfected cells with the BiFC system.
We analyzed and categorized transfected cells in different categories. Scale bar: 30 μm. b WT aSyn resulted in an increased percentage of cells
with fragmented Golgi morphology when compared with the empty vector and with cells expressing the A53E mutant. c-d Representative
pictures of transfected cells with SynT + Synphilin-1. Scale bar: 30 μm. d In the presence of A53E SynT, the Golgi is more diffuse when compared
with the control and with WT SynT. n = 3
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at position 53 (A53T) with WT protein. We found that the
aggregation of A53T aSyn was identical to that of WT aSyn
[32], suggesting again that the change in charge at position
53 may influence the initial steps of the aggregation process
(dimerization/oligomerization) of aSyn, and not the later
steps that culminate with the formation of the mature in-
clusions. Also, the differences might result by difference
spatial sequestration of aSyn. Misfolded proteins can be tar-
getted to specific compartments, like aggresomes, to facili-
tate their degradation [23, 24, 62]. These compartments
rely on filament network proteins like vimentin, actin, and
tubulin, or proteins that can assist in the transportation of
misfolded proteins through the microtubule network, such
as p62 (24843142, 12093283, 14623963, 24086678). For ex-
ample, Tubulin Polymerization Promoting Protein (TPPP/
p25), belongs to the microtubule network, and associates
with aSyn in pathological conditions, possibly affecting
aSyn aggregation (17123092).
The Golgi apparatus plays a determinant role in the
intracellular flow of several endogenous proteins and ex-
ogenous macromolecules, regulating the trafficking to
their final destination inside or outside cells [12]. Frag-
mentation of the Golgi apparatus is a characteristic fea-
ture in several neurodegenerative diseases, including PD
[13, 18, 19]. Interestingly, in our cell-based aggregation
models, we observed a striking loss of the typical Golgi
morphology in cells expressing A53E aSyn. Previous
studies about the effect of this recently identified PD
mutation in aSyn showed that A53E is as toxic as WT
aSyn [15, 50]. While this was also the trend we observed
in our cellular models, our findings suggest that the A53E
mutant may cause specific alterations in cell physiology
Fig. 6 Phenotypic characterization of yeast cells expressing the A53E aSyn mutant. a Cytotoxicity of WT and A53E aSyn in yeast cells compared
to the empty vector, assessed by spotting assay. Photos were taken 3 days after incubation at 30 °C. b Frequency of PI positive cells assessed by
flow cytometry, after 7 h of induction of expression of WT and A53E aSyn. c Fluorescence microscopy visualization (left panel) and percentage of
cells with WT and A53E aSyn inclusions (right panel). d Expression levels of WT and A53E aSyn-GFP in yeast cells assessed by western blot analysis
of total protein extracts. Results shown are from one representative experiment from at least three independent experiments. Values represent
the mean ± SD of at least three independent measurements
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that are still not understood and demand additional
investigation.
Conclusions
Overall, our study demonstrates that the A53E aSyn mu-
tation influences the ability of aSyn to aggregate in vitro
and in vivo, and that it may induce different cellular
pathologies that should be further investigated in vivo.
Ultimately, a deeper understanding of the effect of aSyn
mutations on the behavior of the protein will enable
the design of novel models to assess the potential
value of future therapeutic strategies for PD and other
synucleinopathies.
Additional file
Additional file 1: Figure S1.1. Biochemical characterization of WT and
A53E recombinant aSyn. Analysis of purified WT and A53E aSyn variants
by SDS-PAGE (18%) stained with Coomassie Brilliant Blue. S1.2. MALDI-TOF
mass spectrometry analysis of purified WT (up) and A53E (down) aSyn
variants. A MW of 14462.98 Da was obtained for WT (theoretical of
14460.16 da) and of 14519.47 Da for A53E (theoretical of 14518.19 Da)
aSyn variants. The peaks of 7231.82 and 7260.97 Da correspond to the
M+2 ions of WT and A53E aSyn, respectively. Figure S2.1 and S2.2.
Immunoblot quantifications. Levels of VN-aSyn (S2.1) and aSyn-VC
(S2.1). n=3. Figure S3.1-S3.3. Morphological analysis of Golgi apparatus
in the aSyn BiFC system. The morphology of the Golgi was analyzed as
normal (S3.1), diffuse (S3.2) and fragmented (S3.3). One-way ANOVA
with post-hoc Tukey’s test (*p<0.05, **p<0.01, ***p<0.001). n=3. Figure
S3.4-3.6 Morphological analysis of Golgi apparatus in the aSyn
aggregation model. Transfected cells were analyzed according to the
morphology of the Golgi: normal (S3.4), diffuse (S3.5) and fragmented
(S3.6) One-way ANOVA with post-hoc Tukey’s test (*p<0.05, **p<0.01,
***p<0.001). n=3. (PDF 389 kb)
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